Document Detail


Effects of food on the single-dose pharmacokinetics/pharmacodynamics of tizanidine capsules and tablets in healthy volunteers.
MedLine Citation:
PMID:  17062304     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: A multiparticulate capsule formulation of the alpha2-adrenergic agonist tizanidine has been developed to decrease C(max), AUC, and associated somnolence, while maintaining efficacy. OBJECTIVE: The purpose of this study was to compare the pharmacokinetics and impact of somnolence on cognitive function after single doses of the tablet and capsule formulations of tizanidine under fed and fasted conditions in healthy volunteers. METHODS: This Phase I, single-dose, randomized, open-label, 4-way crossover study was conducted at MDS Pharma Services, Belfast, United Kingdom. Healthy male and female adult subjects received tizanidine (8 mg) as tablets and capsules under fasting and nonfasting conditions. Blood samples were collected to determine plasma tizanidine pharmacokinetic profiles, and computerized cognitive function tests were performed that yielded a validated composite score, Power of Attention, an index of sedation. RESULTS: Ninety-six patients were enrolled in the study (54 men, 42 women; mean [SD] age, 27 [8] years [range, 18-52 years]; mean [SD] body weight, 71.7 [12.4] kg [range, 46-102 kg]). Tizanidine tablets and capsules were found to be bioequivalent after fasting. In the fed state, mean C(max) and AUC(0-t) were substantially decreased, by 33.8% and 15.4%, comparing the capsules and tablets, respectively. The median T(max) increased significantly from 1.41 to 3.0 hours (P < 0.001). Administration of the capsules with food resulted in <20% difference in mean C(max) and AUC(0-t) compared with the fasting state, whereas mean C(max) and AUC(0-t) were 22.6% and 45.2% higher when the tablet formulation was administered with food. The onset of impairment in Power of Attention was significantly delayed from 0.75 to 1.5 hours postdose when capsules were administered with food compared with the other conditions (P < 0.001). The most commonly reported adverse events were asthenia, somnolence, and orthostatic hypotension. A significantly lower adverse event rate was observed in the combined capsules group compared with the tablets, suggesting that differences in tolerability may exist. CONCLUSIONS: The results of this study in healthy volunteers suggest that the capsule and tablet formulations of tizanidine were bioequivalent only in the fasted state. The capsule formulation exhibited a food effect that reduced C(max) and AUC(0-t), and significantly increased T(max), which was associated with a delay in cognitive impairment. The large interpatient variability in plasma profiles most likely dampened the ability to fully elucidate the differences between the 2 formulations.
Authors:
Jaymin Shah; Keith A Wesnes; Rosemary A Kovelesky; Herbert R Henney
Related Documents :
1864954 - Intestinal absorption of magnesium from food and supplements.
12791614 - Inhibition of cholesterol absorption by phytosterol-replete wheat germ compared with ph...
7628834 - Pharmacokinetic and bioavailability of diltiazem sustained-release: influence of food a...
20686624 - Bioequivalence of the 4-mg oral granules and chewable tablet formulations of montelukast.
24351744 - The potential link between gut microbiota and ige-mediated food allergy in early life.
10486364 - Characterisation of immune mediator release during the immediate response to segmental ...
Publication Detail:
Type:  Clinical Trial, Phase I; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Clinical therapeutics     Volume:  28     ISSN:  0149-2918     ISO Abbreviation:  Clin Ther     Publication Date:  2006 Sep 
Date Detail:
Created Date:  2006-10-25     Completed Date:  2007-01-11     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7706726     Medline TA:  Clin Ther     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1308-17     Citation Subset:  IM    
Affiliation:
Elan Pharmaceuticals, Inc., San Diego, California, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Adult
Capsules
Clonidine / administration & dosage,  analogs & derivatives*,  pharmacokinetics
Cognition / drug effects*,  physiology
Cross-Over Studies
Disorders of Excessive Somnolence / blood*,  psychology
Female
Follow-Up Studies
Gas Chromatography-Mass Spectrometry
Humans
Male
Middle Aged
Muscle Relaxants, Central / administration & dosage,  pharmacokinetics*
Reference Values
Tablets
Chemical
Reg. No./Substance:
0/Capsules; 0/Muscle Relaxants, Central; 0/Tablets; 4205-90-7/Clonidine; 51322-75-9/tizanidine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Effects of 3-day IV pantoprazole versus omeprazole on 24-hour intragastric acidity at 3 days in Chin...
Next Document:  Sustained-release versus immediate-release glipizide for treatment of type 2 diabetes mellitus in ch...